Lupin Infringes Exeltis Contraceptive Patents, Judge Finds

By Leslie A. Pappas · September 5, 2024, 7:53 PM EDT

Mumbai-based generic-pharmaceuticals company Lupin Pharmaceuticals Inc. has infringed five patents of the estrogen-free contraceptive Slynd, a Delaware federal judge said Wednesday, finding in favor of Spanish pharmaceutical company Insud Pharma and...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Case Information

Case Title

Exeltis USA, Inc. et al v. Lupin Ltd. et al

Case Number

Court

Delaware

Nature of Suit

Patent - Abbreviated New Drug Application(ANDA)

Date Filed

April 01, 2022

Recent Articles By Leslie

August 15, 2024
Del. Chancery OKs $175M Judgment Against Insys Founder
August 01, 2024
Medtronic Still Faces Chancery Claim In Fortis' InPen Suit
July 12, 2024
Chancery Approves $19.5M Convey-TPG Settlement
June 25, 2024
Chancery OKs $71M Premier Deal, $14M Four-Firm Fee
June 21, 2024
Ex-CEO Found Liable For $1 Now Seeks Atty Fees For Del. Suit
June 12, 2024
Directors Of Defunct Med Tech SPAC Seek Toss Of Del. Suit
May 21, 2024
SPAC Investor's Suit Changes Came Too Late, Chancery Rules
May 17, 2024
EndoStim Emerges From Delaware Insolvency Proceeding
May 02, 2024
Investors Not Entitled To Info, Sequel Youth Tells Chancery
May 01, 2024
'Foul' BioVentrix Cash-Out Gets Extra Scrutiny, Chancery Says